KYMERA THERAPEUTICS I

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

28 Feb 2024 07:00:10 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

22 Feb 2024 07:00:01 By Nasdaq GlobeNewswire

Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22

15 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference

31 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs

09 Jan 2024 09:17:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

09 Jan 2024 09:15:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Pricing of $275 Million Public Offering

05 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Proposed Public Offering

04 Jan 2024 16:01:00 By Nasdaq GlobeNewswire

R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases

04 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024

02 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4

13 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting

10 Dec 2023 21:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi

07 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine

13 Nov 2023 11:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting

02 Nov 2023 09:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update

02 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

01 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi

27 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2

26 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma

16 Oct 2023 07:00:00 By Nasdaq GlobeNewswire